Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending
From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share of Medicare’s pharmacy bill.
This visualization, via Visual Capitalist’s Pallavi Rao, ranks the most common drugs by total Medicare spending in 2023, sourced from Centers for Medicare & Medicaid Services
It tracks every claim, dosage, and dollar flowing through Medicare Part D, the federal prescription-drug benefit.
Blood Thinners Are America’s Most Common Drug
Eliquis (generic name: Apixaban) alone racked up $18.3 billion in Medicare spending in 2023, nearly double the next drug, Ozempic.
Alongside Xarelto, anticoagulants accounted for over $24 billion in 2023.
| Rank | Country | Region | Years in Poor Health | HALE, 2021 | Average Life Expectancy, 2025 |
|---|---|---|---|---|---|
| 1 | Bahrain |
Asia | 17.4 | 64.2 | 81.6 |
| 2 | Oman |
Asia | 17.3 | 63.2 | 80.5 |
| 3 | Eswatini |
Africa | 16.9 | 47.5 | 64.4 |
| 4 | Qatar |
Asia | 16.5 | 66.2 | 82.7 |
| 5 | Botswana |
Africa | 16.3 | 53.1 | 69.4 |
| 6 | Afghanistan |
Asia | 16.1 | 50.4 | 66.5 |
| 7 | UAE |
Asia | 15.9 | 67.3 | 83.2 |
| 8 | U.S. |
Northern America | 15.7 | 63.9 | 79.6 |
| 9 | Peru |
Southern America | 15.1 | 63.0 | 78.1 |
| 10 | Lebanon |
Asia | 14.9 | 63.2 | 78.1 |
| 11 | Namibia |
Africa | 14.9 | 52.8 | 67.7 |
| 12 | Maldives |
Asia | 14.8 | 66.7 | 81.5 |
| 13 | Brazil |
Southern America | 14.4 | 61.8 | 76.2 |
| 14 | India |
Asia | 14.4 | 58.1 | 72.5 |
| 15 | Mozambique |
Africa | 14.3 | 49.7 | 64.0 |
| 16 | Iran |
Asia | 14.1 | 64.0 | 78.1 |
| 17 | North Macedonia |
Europe | 14.0 | 63.7 | 77.7 |
| 18 | Mexico |
Americas | 14.0 | 61.4 | 75.4 |
| 19 | Micronesia |
Oceania | 13.9 | 57.9 | 71.8 |
| 20 | Chile |
Southern America | 13.8 | 67.7 | 81.5 |
| 21 | Cuba |
Americas | 13.8 | 64.6 | 78.4 |
| 22 | Eritrea |
Africa | 13.8 | 55.4 | 69.2 |
| 23 | Slovakia |
Europe | 13.8 | 64.9 | 78.7 |
| 24 | South Africa |
Africa | 13.7 | 52.8 | 66.5 |
| 25 | Zambia |
Africa | 13.7 | 53.0 | 66.7 |
| 26 | Greece |
Europe | 13.6 | 68.6 | 82.2 |
| 27 | Guatemala |
Americas | 13.6 | 59.3 | 72.9 |
| 28 | Bulgaria |
Europe | 13.6 | 62.4 | 76.0 |
| 29 | Suriname |
Southern America | 13.6 | 60.3 | 73.9 |
| 30 | Australia |
Oceania | 13.6 | 70.6 | 84.2 |
| 31 | Guyana |
Southern America | 13.6 | 56.8 | 70.4 |
| 32 | Lesotho |
Africa | 13.6 | 44.6 | 58.2 |
| 33 | Costa Rica |
Americas | 13.6 | 67.6 | 81.2 |
| 34 | Saudi Arabia |
Asia | 13.6 | 65.6 | 79.2 |
| 35 | France |
Europe | 13.5 | 70.1 | 83.6 |
| 36 | Uruguay |
Southern America | 13.5 | 65.0 | 78.5 |
| 37 | Poland |
Europe | 13.5 | 65.5 | 79.0 |
| 38 | Ecuador |
Southern America | 13.5 | 64.3 | 77.8 |
| 39 | Czechia |
Europe | 13.4 | 66.7 | 80.1 |
| 40 | Italy |
Europe | 13.4 | 70.6 | 84.0 |
| 41 | Solomon Islands |
Oceania | 13.4 | 57.4 | 70.8 |
| 42 | Bahamas |
Americas | 13.4 | 61.5 | 74.9 |
| 43 | Morocco |
Africa | 13.4 | 62.3 | 75.7 |
| 44 | Ukraine |
Europe | 13.3 | 61.6 | 74.9 |
| 45 | Tunisia |
Africa | 13.3 | 63.6 | 76.9 |
| 46 | Albania |
Europe | 13.3 | 66.7 | 80.0 |
| 47 | Puerto Rico |
Americas | 13.3 | 68.8 | 82.1 |
| 48 | Panama |
Americas | 13.3 | 66.7 | 80.0 |
| 49 | Serbia |
Europe | 13.2 | 63.9 | 77.1 |
| 50 | Paraguay |
Southern America | 13.2 | 60.9 | 74.1 |
| 51 | Bosnia and Herzegovina |
Europe | 13.2 | 65.0 | 78.2 |
| 52 | Portugal |
Europe | 13.2 | 69.5 | 82.7 |
| 53 | Honduras |
Americas | 13.2 | 60.0 | 73.2 |
| 54 | Kazakhstan |
Asia | 13.1 | 61.6 | 74.7 |
| 55 | Yemen |
Asia | 13.1 | 56.5 | 69.6 |
| 56 | Vanuatu |
Oceania | 13.1 | 58.7 | 71.8 |
| 57 | Canada |
Northern America | 13.1 | 69.8 | 82.9 |
| 58 | Colombia |
Southern America | 13.1 | 65.0 | 78.1 |
| 59 | Malaysia |
Asia | 13.1 | 63.9 | 77.0 |
| 60 | Switzerland |
Europe | 13.1 | 71.1 | 84.2 |
| 61 | Kiribati |
Oceania | 13.1 | 53.6 | 66.7 |
| 62 | Jordan |
Asia | 13.0 | 65.1 | 78.1 |
| 63 | Malawi |
Africa | 13.0 | 54.7 | 67.7 |
| 64 | Kuwait |
Asia | 13.0 | 67.8 | 80.8 |
| 65 | UK |
Europe | 13.0 | 68.6 | 81.6 |
Their rise reflects both an aging population and expanding preventative treatment for stroke and atrial fibrillation.
With almost four million beneficiaries, Eliquis is prescribed to roughly one in 10 Part D enrollees.
Related: See the 25 countries that are projected have the most seniors in 2050.
Diabetes and Weight-Loss Therapies Surge in America
Four GLP-1 and SGLT2 diabetes drugs—Ozempic, Jardiance, Trulicity, and Farxiga—collectively totaled $29.7 billion.
Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro also double as weight-loss aids, driving demand beyond traditional type-2 diabetes patients.
This table lists cost per dose for the 10 most expensive drugs.
Their high list prices—Ozempic averages $356 per dose—illustrate how novel biologics multiply spending even with smaller patient counts.
Related: See where Americans skipped going to the doctor (even when they had to) in 2023.
Cancer and Autoimmune Biologics are Expensive Drugs
Revlimid, Humira, and Stelara each exceed $3 billion despite treating fewer than 100,000 beneficiaries each.
Revlimid’s $878 per dose and Stelara’s staggering $26,818 underscore why biologics dominate specialty-drug budgets.
Want more health-related data storytelling? Check out Ranked: Countries That Spend the Most Years in Poor Health on Voronoi, the new app from Visual Capitalist.
Tyler Durden Wed, 10/22/2025 – 21:20
Source: https://freedombunker.com/2025/10/22/blood-thinners-anti-obesity-shots-dominate-medicare-drug-spending/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

Bahrain
Oman
Eswatini
Qatar
Botswana
Afghanistan
UAE
U.S.
Peru
Lebanon
Namibia
Maldives
Brazil
India
Mozambique
Iran
North Macedonia
Mexico
Micronesia
Chile
Cuba
Eritrea
Slovakia
South Africa
Zambia
Greece
Guatemala
Bulgaria
Suriname
Australia
Guyana
Lesotho
Costa Rica
Saudi Arabia
France
Uruguay
Poland
Ecuador
Czechia
Italy
Solomon Islands
Bahamas
Morocco
Ukraine
Tunisia
Albania
Puerto Rico
Panama
Serbia
Paraguay
Bosnia and Herzegovina
Portugal
Honduras
Kazakhstan
Yemen
Vanuatu
Canada
Colombia
Malaysia
Switzerland
Kiribati
Jordan
Malawi
Kuwait
UK

